Phase 4
Completed N=81
1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
Source: ClinicalTrials.gov NCT02334722 ↗Enrolled (actual)
81
Serious AEs
23.7%
Results posted
Dec 2021
Primary outcomePrimary: Change in Neurotoxicity Scale Scores — -1; -3.5 score on scale — p=0.7824
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Neurotoxicity Scale Scores |
-1; -3.5 | 0.7824 |
Eligibility Criteria
Inclusion Criteria
- Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.
- Able to be randomized prior to or up to 48 hours after surgery.
Exclusion Criteria
- No known history of seizure activity.
- Pregnant or breastfeeding.
- Renal dysfunction (CrCl < 30ml/min).
- Beck's Depression Inventory (BDI) ≥14
- Allergy to levetiracetam.
Data sourced from ClinicalTrials.gov (NCT02334722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.